Opinion|Videos|June 18, 2024

Navigating Therapy Approval for Early Breast Cancer: An Operational Perspective

Medical experts discuss their perspectives on therapy approval and the significance of formulary inclusion, emphasizing the need to carefully consider both toxicities and benefits, which may ultimately lead to the operationalization of a drug in clinical practice.

Video content above is prompted by the following questions:

How will the potential approval of ribociclib for early breast cancer change your treatment paradigms?

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.


Latest CME